Heroin-assisted treatment of heroin-addicted patients normalizes regulatory T cells but does not restore CD4
CD4+ T cells
heroin
heroin-assisted treatment
methadone
regulatory T cells
Journal
Addiction biology
ISSN: 1369-1600
Titre abrégé: Addict Biol
Pays: United States
ID NLM: 9604935
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
revised:
12
10
2020
received:
30
07
2020
accepted:
19
11
2020
pubmed:
19
12
2020
medline:
15
12
2021
entrez:
18
12
2020
Statut:
ppublish
Résumé
Heroin dependence may result in suppression of adaptive immune responses. Previously, we demonstrated an increase in relative numbers of inhibitory CD4
Substances chimiques
Analgesics, Opioid
0
Cytokines
0
Heroin
70D95007SX
Methadone
UC6VBE7V1Z
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e12998Informations de copyright
© 2020 The Authors. Addiction Biology published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction.
Références
Farrell M, Ward J, Mattick R, et al. Methadone maintenance treatment in opiate dependence: a review. BMJ. 1994;309(6960):997-1001.
Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2003;2:CD002209.
Gowing L, Farrell M, Bornemann R, Ali R. Substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. 2004;4:CD004145.
Bao YP, Liu ZM, Epstein DH, Du C, Shi J, Lu L. A meta-analysis of retention in methadone maintenance by dose and dosing strategy. Am J Drug Alcohol Abuse. 2009;35(1):28-33.
Bell J, Burrell T, Indig D, Gilmour S. Cycling in and out of treatment; participation in methadone treatment in NSW, 1990-2002. Drug Alcohol Depend. 2006;81(1):55-61.
Specka M, Bonnet U, Heilmann M, Schifano F, Scherbaum N. Longitudinal patterns of benzodiazepine consumption in a German cohort of methadone maintenance treatment patients. Hum Psychopharmacol. 2011;26(6):404-411.
McCarty D, Priest KC, Korthuis PT. Treatment and prevention of opioid use disorder: challenges and opportunities. Annu Rev Public Health. 2018;39:525-541.
Ndegwa S, Pant S, Pohar S, Mierzwinski-Urban M. Injectable Extended-Release Naltrexone to Treat Opioid Use Disorder. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016.
Perneger TV, Giner F, del Rio M, Mino A. Randomised trial of heroin maintenance programme for addicts who fail in conventional drug treatments. BMJ. 1998;317(7150):13-18.
van den Brink W, Hendriks VM, Blanken P, Koeter MW, van Zwieten BJ, van Ree JM. Medical prescription of heroin to treatment resistant heroin addicts: two randomised controlled trials. BMJ. 2003;327(7410):310.
March JC, Oviedo-Joekes E, Perea-Milla E, Carrasco F, team P. Controlled trial of prescribed heroin in the treatment of opioid addiction. J Subst Abuse Treat. 2006;31(2):203-211.
Haasen C, Verthein U, Degkwitz P, Berger J, Krausz M, Naber D. Heroin-assisted treatment for opioid dependence: randomised controlled trial. Br J Psychiatry. 2007;191:55-62.
Oviedo-Joekes E, Brissette S, Marsh DC, et al. Diacetylmorphine versus methadone for the treatment of opioid addiction. N Engl J Med. 2009;361(8):777-786.
Strang J, Groshkova T, Uchtenhagen A, et al. Heroin on trial: systematic review and meta-analysis of randomised trials of diamorphine-prescribing as treatment for refractory heroin addictiondagger. Br J Psychiatry. 2015;207(1):5-14.
Bell J, Belackova V, Lintzeris N. Supervised injectable opioid treatment for the management of opioid dependence. Drugs. 2018;78(13):1339-1352.
Brett MM, Hood J, Brazier JS, Duerden BI, Hahne SJ. Soft tissue infections caused by spore-forming bacteria in injecting drug users in the United Kingdom. Epidemiol Infect. 2005;133(4):575-582.
Grunow R, Klee SR, Beyer W, et al. Anthrax among heroin users in Europe possibly caused by same Bacillus anthracis strain since 2000. Euro Surveill. 2013;18(13):20437.
Roy S, Ninkovic J, Banerjee S, et al. Opioid drug abuse and modulation of immune function: consequences in the susceptibility to opportunistic infections. J Neuroimmune Pharmacol. 2011;6(4):442-465.
Govitrapong P, Suttitum T, Kotchabhakdi N, Uneklabh T. Alterations of immune functions in heroin addicts and heroin withdrawal subjects. J Pharmacol Exp Ther. 1998;286(2):883-889.
Nair MP, Laing TJ, Schwartz SA. Decreased natural and antibody-dependent cellular cytotoxic activities in intravenous drug abusers. Clin Immunol Immunopathol. 1986;38(1):68-78.
Novick DM, Ochshorn M, Ghali V, et al. Natural killer cell activity and lymphocyte subsets in parenteral heroin abusers and long-term methadone maintenance patients. J Pharmacol Exp Ther. 1989;250(2):606-610.
Riss GL, Chang DI, Wevers C, et al. Opioid maintenance therapy restores CD4+ T cell function by normalizing CD4+CD25(high) regulatory T cell frequencies in heroin user. Brain Behav Immun. 2012;26(6):972-978.
Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell. 2008;133(5):775-787.
Seddiki N, Santner-Nanan B, Martinson J, et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med. 2006;203(7):1693-1700.
Abel S, Luckheide N, Westendorf AM, et al. Strong impact of CD4+ Foxp3+ regulatory T cells and limited effect of T cell-derived IL-10 on pathogen clearance during Plasmodium yoelii infection. J Immunol. 2012;188(11):5467-5477.
Jost NH, Abel S, Hutzler M, et al. Regulatory T cells and T-cell-derived IL-10 interfere with effective anti-cytomegalovirus immune response. Immunol Cell Biol. 2014;92(10):860-871.
Pastille E, Bardini K, Fleissner D, et al. Transient ablation of regulatory T cells improves antitumor immunity in colitis-associated colon cancer. Cancer Res. 2014;74(16):4258-4269.
Sacerdote P, Franchi S, Gerra G, Leccese V, Panerai AE, Somaini L. Buprenorphine and methadone maintenance treatment of heroin addicts preserves immune function. Brain Behav Immun. 2008;22(4):606-613.
Liang X, Liu R, Chen C, Ji F, Li T. Opioid system modulates the immune function: a review. Transl Perioper Pain Med. 2016;1(1):5-13.
Baral S, Sherman SG, Millson P, Beyrer C. Vaccine immunogenicity in injecting drug users: a systematic review. Lancet Infect Dis. 2007;7(10):667-674.
Zhou Y, Sun L, Wang X, et al. Heroin use promotes HCV infection and dysregulates HCV-related circulating microRNAs. J Neuroimmune Pharmacol. 2015;10(1):102-110.
Friedman H, Pross S, Klein TW. Addictive drugs and their relationship with infectious diseases. FEMS Immunol Med Microbiol. 2006;47(3):330-342.
Moroz E, Albrecht RA, Aden B, et al. Active opioid use does not attenuate the humoral responses to inactivated influenza vaccine. Vaccine. 2016;34(11):1363-1369.
Wang J, Barke RA, Ma J, Charboneau R, Roy S. Opiate abuse, innate immunity, and bacterial infectious diseases. Arch Immunol Ther Exp (Warsz). 2008;56(5):299-309.
Asakura H, Kawamoto K, Igimi S, Yamamoto S, Makino S. Enhancement of mice susceptibility to infection with Listeria monocytogenes by the treatment of morphine. Microbiol Immunol. 2006;50(7):543-547.
Feng P, Rahim RT, Cowan A, et al. Effects of mu, kappa or delta opioids administered by pellet or pump on oral salmonella infection and gastrointestinal transit. Eur J Pharmacol. 2006;534(1-3):250-257.
Wang J, Barke RA, Charboneau R, Schwendener R, Roy S. Morphine induces defects in early response of alveolar macrophages to Streptococcus pneumoniae by modulating TLR9-NF-kappa B signaling. J Immunol. 2008;180(5):3594-3600.
Neri S, Bruno CM, Pulvirenti D, et al. Randomized clinical trial to compare the effects of methadone and buprenorphine on the immune system in drug abusers. Psychopharmacology (Berl). 2005;179(3):700-704.
Akbari A, Mosayebi G, Samiei AR, Ghazavi A. Methadone therapy modulate the dendritic cells of heroin addicts. Int Immunopharmacol. 2019;66:330-335.
Schneider S, Meys F. Analysis of illicit cocaine and heroin samples seized in Luxembourg from 2005-2010. Forensic Sci Int. 2011;212(1-3):242-246.
Reimer J, Verthein U, Karow A, Schafer I, Naber D, Haasen C. Physical and mental health in severe opioid-dependent patients within a randomized controlled maintenance treatment trial. Addiction. 2011;106(9):1647-1655.
Rangassamy M, Khaleghparast Athari S, Monclus R, Boissier MC, Bessis N, Rodel HG. Personality modulates proportions of CD4(+) regulatory and effector T cells in response to socially induced stress in a rodent of wild origin. Physiol Behav. 2016;167:255-264.
Kiank C, Holtfreter B, Starke A, Mundt A, Wilke C, Schutt C. Stress susceptibility predicts the severity of immune depression and the failure to combat bacterial infections in chronically stressed mice. Brain Behav Immun. 2006;20(4):359-368.
Hoglund CO, Axen J, Kemi C, et al. Changes in immune regulation in response to examination stress in atopic and healthy individuals. Clin Exp Allergy. 2006;36(8):982-992.
Ronaldson A, Gazali AM, Zalli A, et al. Increased percentages of regulatory T cells are associated with inflammatory and neuroendocrine responses to acute psychological stress and poorer health status in older men and women. Psychopharmacology (Berl). 2016;233(9):1661-1668.
Cain DW, Cidlowski JA. Immune regulation by glucocorticoids. Nat Rev Immunol. 2017;17(4):233-247.
Karagiannidis C, Akdis M, Holopainen P, et al. Glucocorticoids upregulate FOXP3 expression and regulatory T cells in asthma. J Allergy Clin Immunol. 2004;114(6):1425-1433.
Walter M, Gerhard U, Gerlach M, Weijers HG, Boening J, Wiesbeck GA. Cortisol concentrations, stress-coping styles after withdrawal and long-term abstinence in alcohol dependence. Addict Biol. 2006;11(2):157-162.
Walter M, Gerber H, Kuhl HC, et al. Acute effects of intravenous heroin on the hypothalamic-pituitary-adrenal axis response: a controlled trial. J Clin Psychopharmacol. 2013;33(2):193-198.
Walter M, Wiesbeck GA, Degen B, et al. Heroin reduces startle and cortisol response in opioid-maintained heroin-dependent patients. Addict Biol. 2011;16(1):145-151.
Walter M, Wiesbeck GA, Bloch N, et al. Psychobiological responses to drug cues before and after methadone intake in heroin-dependent patients: a pilot study. Eur Neuropsychopharmacol. 2008;18(5):390-393.
Weber RJ, Gomez-Flores R, Smith JE, Martin TJ. Neuronal adaptations, neuroendocrine and immune correlates of heroin self-administration. Brain Behav Immun. 2009;23(7):993-1002.
Brown JN, Ortiz GM, Angel TE, et al. Morphine produces immunosuppressive effects in nonhuman primates at the proteomic and cellular levels. Mol Cell Proteomics. 2012;11(9):605-618.
Eisenstein TK. The role of opioid receptors in immune system function. Front Immunol. 2019;10:2904.
Rossi GC, Brown GP, Leventhal L, Yang K, Pasternak GW. Novel receptor mechanisms for heroin and morphine-6 beta-glucuronide analgesia. Neurosci Lett. 1996;216(1):1-4.
Philippe D, Chakass D, Thuru X, et al. Mu opioid receptor expression is increased in inflammatory bowel diseases: implications for homeostatic intestinal inflammation. Gut. 2006;55(6):815-823.
Borner C, Kraus J, Bedini A, Schraven B, Hollt V. T-cell receptor/CD28-mediated activation of human T lymphocytes induces expression of functional mu-opioid receptors. Mol Pharmacol. 2008;74(2):496-504.
Wang J, Charboneau R, Balasubramanian S, Barke RA, Loh HH, Roy S. Morphine modulates lymph node-derived T lymphocyte function: role of caspase-3, −8, and nitric oxide. J Leukoc Biol. 2001;70(4):527-536.
Franchi S, Moschetti G, Amodeo G, Sacerdote P. Do all opioid drugs share the same Immunomodulatory properties? A review from animal and human studies. Front Immunol. 2019;10:2914.
Boerrigter G, Soergel DG, Violin JD, Lark MW, Burnett JC Jr. TRV120027, a novel beta-arrestin biased ligand at the angiotensin II type I receptor, unloads the heart and maintains renal function when added to furosemide in experimental heart failure. Circ Heart Fail. 2012;5(5):627-634.
Tarigopula M, Davis RT 3rd, Mungai PT, et al. Cardiac myosin light chain phosphorylation and inotropic effects of a biased ligand, TRV120023, in a dilated cardiomyopathy model. Cardiovasc Res. 2015;107(2):226-234.
Keith DE, Murray SR, Zaki PA, et al. Morphine activates opioid receptors without causing their rapid internalization. J Biol Chem. 1996;271(32):19021-19024.
Sternini C, Spann M, Anton B, et al. Agonist-selective endocytosis of mu opioid receptor by neurons in vivo. Proc Natl Acad Sci U S a. 1996;93(17):9241-9246.
Alvarez VA, Arttamangkul S, Dang V, et al. mu-Opioid receptors: ligand-dependent activation of potassium conductance, desensitization. Int J Neurosci. 2002;22(13):5769-5776.
Borner C, Lanciotti S, Koch T, Hollt V, Kraus J. Mu opioid receptor agonist-selective regulation of interleukin-4 in T lymphocytes. J Neuroimmunol. 2013;263(1-2):35-42.
Smith JS, Nicholson LT, Suwanpradid J, et al. Biased agonists of the chemokine receptor CXCR3 differentially control chemotaxis and inflammation. Sci Signal. 2018;11(555):eaaq1075.
Smith JS, Rajagopal S. The beta-Arrestins: multifunctional regulators of G protein-coupled receptors. J Biol Chem. 2016;291(17):8969-8977.
Soergel DG, Subach RA, Burnham N, et al. Biased agonism of the mu-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: a randomized, double-blind, placebo-controlled, crossover study in healthy volunteers. Pain. 2014;155(9):1829-1835.
Manglik A, Lin H, Aryal DK, et al. Structure-based discovery of opioid analgesics with reduced side effects. Nature. 2016;537(7619):185-190.
Porter-Stransky KA, Weinshenker D. Arresting the development of addiction: the role of beta-Arrestin 2 in drug abuse. J Pharmacol Exp Ther. 2017;361(3):341-348.